ArticleCancer biomarkers : section A of Disease markers2018
Clinical potential of miR-940 as a diagnostic and prognostic biomarker in breast cancer patients.
Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Identification of novel exosomal miRNAs and their role in diagnosis and prognosis of triple negative breast cancer.BMC cancer · 2026Article
- CircPLK1 upregulates ETS1 to confer anthracycline resistance in triple-negative breast cancer.Journal of translational internal medicine · 2025Article
- Correlation of Wilms' Tumor 1 (WT1) with Oxidative Stress Markers and Expression of miR-361-5p; New Aspect of WT1 in Breast Cancer.Indian journal of clinical biochemistry : IJCB · 2023Article
- JHDM1D-AS1-driven inhibition of miR-940 releases ARTN expression to induce breast carcinogenesis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Unique microRNA expression profiles in plasmic exosomes from intrahepatic cholestasis of pregnancy.BMC pregnancy and childbirth · 2023Article
- Review
- Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer.Non-coding RNA · 2022Review
- Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer.Journal of healthcare engineering · 2022Article
- Optimization of a method for the clinical detection of serum exosomal miR-940 as a potential biomarker of breast cancer.Frontiers in oncology · 2022Article
- A Four-miRNA-Based Diagnostic Signature for Rheumatoid Arthritis.Disease markers · 2022Article
- DecreasedTranslational lung cancer research · 2021Article
- miR-940 is a new biomarker with tumor diagnostic and prognostic value.Molecular therapy. Nucleic acids · 2021Review
- The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer.Nutrients · 2021Review
- miR‑653‑5p suppresses the growth and migration of breast cancer cells by targeting MAPK6.Molecular medicine reports · 2021Article
- MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer.Frontiers in oncology · 2021Article
- Development of a Novel Immune Infiltration-Related ceRNA Network and Prognostic Model for Sarcoma.Frontiers in cell and developmental biology · 2021Article
- MiR-940 Serves as a Diagnostic Biomarker in Patients with Sepsis and Regulates Sepsis-Induced Inflammation and Myocardial Dysfunction.Journal of inflammation research · 2021Article
- MicroRNA-623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer.Oncology letters · 2020Article
- Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes.Journal of personalized medicine · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer remains the most invasive female malignancy worldwide. Functional role of microRNA-940 (miR-940) have been investigated in various cancer. The purpose of this study was to assess the serum miR-940 expression and its clinical significance in breast cancer.
methodsExpression of miR-940 was measured by quantitative real-time polymerase chain reaction (qRT-PCR). The diagnostic value of miR-940 was analyzed with receiver operating characteristics (ROC) analysis. To explore the prognostic performance of miR-940, Kaplan-Meier survival assay and Cox regression analysis were performed.
resultsDownregulated miR-940 was detected in the breast cancer patients compared with the healthy controls (P< 0.001). The miR-940 expression was correlated with lymph node metastasis (P= 0.014) and TNM stage (P= 0.003). The area under the ROC curve (AUC) was 0.905, with sensitivity and specificity of 94.5% and 78.6%. From the survival curves, patients with low miR-940 expression had poor overall survival compare with those with high expression (log-rank P= 0.009). The Cox analysis indicated that miR-940 was an independent prognostic factor (HR = 2.645, 95% CI = 1.426-4.906 and P= 0.002). Decreased miR-940 expression was also been found in triple-negative breast cancer (TNBC) samples, and might predict poor prognosis in TNBC patients.
conclusionsSerum downregulated miR-940 may serve as a reliable diagnostic and prognostic biomarker in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.